Clinical Report: Dual Action for Bausch + Lomb

Overview

Bausch + Lomb is advancing a dual-action dry eye drop to Phase 3 trials, combining 5% lifitegrast and perfluorohexyloctane (PFHO). The therapy showed significant results in a secondary analysis at Day 15, although it did not meet its primary endpoint at Day 29.

Background

Dry eye disease (DED) is a multifactorial condition that significantly impacts patient quality of life. Current therapies often target either inflammation or tear evaporation, highlighting the need for innovative combination treatments. Bausch + Lomb's investigational therapy aims to address both aspects in a single formulation.

Data Highlights

Key Findings

• The dual-action therapy combines 5% lifitegrast and PFHO in a single formulation.
• Primary endpoint of superiority over lifitegrast alone was not met at Day 29 (p=0.196).
• Significant reduction in mean tCFS change from baseline at Day 15 (p=0.0007).
• 41.6% of patients on the combination achieved a three-unit or greater improvement in tCFS at Day 15.
• BL1332, a TRPV1 antagonist, showed positive Phase 1b results in reducing ocular pain.
• BL1332 is now being evaluated in a Phase 2 study for pain post-photorefractive keratectomy.

Clinical Implications

The advancement of the dual-action therapy to Phase 3 trials indicates a potential shift in the treatment paradigm for dry eye disease. The significant results at Day 15 suggest that this combination therapy may offer rapid relief for patients.

Conclusion

Bausch + Lomb's dual-action eye drop represents a promising approach to treating dry eye disease by addressing both inflammation and tear evaporation. Further results from Phase 3 trials will be critical in determining its efficacy and safety.

Related Resources & Content

1. Bausch + Lomb, Bausch + Lomb Corporation, 2023 -- Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
2. Eyecare Business, Eyecare Business, 2023 -- Bausch + Lomb Acquires Blink from Johnson & Johnson Vision
3. Optometric Management, Optometric Management, 2026 -- Bausch + Lomb Advances Dual-Action Eye Drop for DED to Phase 3 Recommendations
4. Ophthalmology Management, Ophthalmology Management, 2026 -- Bausch + Lomb Advances Dual-Action Eye Drop for DED to Phase 3 Recommendations
5. TFOS DEWS III: Management and Therapy - ScienceDirect, 2025 -- Updated dry eye disease diagnostic methodology and management
6. Contact Lens Spectrum — Bausch Lomb Launches PreservativeFree Version of Blink Triple Care Eye Drops in US
7. TFOS DEWS III: Management and Therapy - ScienceDirect
8. label
9. Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results | Bausch + Lomb Corporation